From April 23rd to 25th, the 66th China International Pharmaceutical Machinery Expo (CIPM) was grandly held in Chongqing International Expo Center. As one of the top events in China's pharmaceutical equipment industry, the expo gathered many famous pharmaceutical equipment enterprises at home and abroad, with an exhibition area of 180,000 square meters, covering innovative technologies and equipment for the whole pharmaceutical industry chain. The exhibition especially set up a synthetic biology exhibition area, focusing on biomanufacturing, gene therapy and other cutting-edge fields, attracting the participation of many industry pioneers, including HOLVES, to discuss technological breakthroughs and industrial upgrading path.
 

 

In the synthetic biology exhibition area, HOLVES showed up with two core equipments - Cla210 lab classic fermenter and K2T-Mini mini tangential flow ultrafiltration system. As an innovative company in the upstream field of synthetic biology, HOLVES demonstrated its key role in bioprocess optimization and industrialization application through equipment display and technology exchange.

The core of synthetic biology lies in the design of biological systems by engineering means, and this process cannot be achieved without efficient and precise fermentation technology. HOLVES' Cla210 series of fermenters is a classic example of laboratory-grade equipment, which is particularly suitable for the cultivation of engineered strains and optimization of metabolic pathways commonly found in synthetic biology, and provides a stable culture environment for artificially constructed biological systems. In the field of synthetic biology, these precision fermenters are becoming an important infrastructure for standardized biomanufacturing.
 

The industrialization of synthetic biology not only relies on upstream strain design, but also requires efficient downstream separation and purification technologies. HOLVES' K2T-Mini mini tangential flow ultrafiltration system is specially optimized for the characteristics of synthetic biology products, and demonstrates its unique advantages in the purification of synthetic products, such as gene therapy vectors and engineered proteins.

The system is particularly suitable for laboratory-scale synthetic biology applications, capable of efficiently processing minute quantities of precious samples to meet the needs of multi-batch and small-volume purification common in synthetic biology research. Its mild separation conditions are especially important for maintaining the biological activity of synthetic biology products, providing reliable technical support for gene circuit construction and artificial cell development.

During the exhibition, the HOLVES team showed visitors in detail the practical application scenarios of the equipment in synthetic biology through on-site demonstration and professional explanation. Many visitors showed great interest in the multiple expansion function of Cla210 fermenter and the automated process control of K2T-Mini, and exchanged technical details with the team in depth. HOLVES technical experts also said that intelligent and modular equipment is the key to break through the bottleneck of biomanufacturing scale-up, and in the future, we will focus on the research and development of high-throughput screening and continuous production technology to help the industry realize the seamless connection from laboratory to factory.
This session of CIPM is not only an industry event, but also an important milestone for synthetic biology to move from concept to practice. In the future, HOLVES will continue to use technology as the spear and demand as the shield to help synthetic biology to open up a wider range of applications.

---

Here is the Holves brand website, https://www.bjholves.com/. Providing different types of industry information, technical knowledge, and solutions, we have developed and produced several new laboratory fermenter, bioreactor, tangential flow filtration system and other equipment to meet your needs from experimental to industrial production.